<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514267</url>
  </required_header>
  <id_info>
    <org_study_id>155-CL-025</org_study_id>
    <nct_id>NCT00514267</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors</brief_title>
  <official_title>A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the feasibility and safety of administering YM155 in combination with docetaxel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is designed to include two parts:

      Part 1: Assessment of feasibility and safety of administering YM155 in combination with
      docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [
      ENROLLMENT COMPLETED ]

      Part 2: Assessment of feasibility and safety of administering YM155 in combination with
      docetaxel in subjects with solid tumors (except HRPC).

      This registration has been updated to reflect the design requirements of PART 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)</measure>
    <time_frame>2 cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors)</measure>
    <time_frame>1 cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and efficacy</measure>
    <time_frame>10 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics</measure>
    <time_frame>Part 1 only</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>1. HRPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM 155</intervention_name>
    <description>IV</description>
    <arm_group_label>1. HRPC</arm_group_label>
    <arm_group_label>2. Solid Tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV</description>
    <arm_group_label>1. HRPC</arm_group_label>
    <arm_group_label>2. Solid Tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. HRPC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1:

          -  Male subjects with histologically or cytologically confirmed adenocarcinoma of the
             prostate with clinical or radiological evidence of metastatic disease.

        Part 2:

          -  Subjects with histologically and cytologically confirmed solid tumors with measurable
             disease (except HRPC).

        Exclusion Criteria:

          -  Radiation therapy within 4 weeks of the start of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <disposition_first_submitted>July 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 13, 2015</disposition_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>HRPC</keyword>
  <keyword>Hormone Refractory Prostate Cancer</keyword>
  <keyword>YM155</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

